ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INDV Indivior PLC

16.53
0.24 (1.47%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Indivior PLC NASDAQ:INDV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.24 1.47% 16.53 16.22 16.86 16.69 16.35 16.35 48,997 00:25:27

Indivior Announces Q3 2023 Financial Results

09/11/2023 7:05am

PR Newswire (US)


Indivior (NASDAQ:INDV)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Indivior Charts.

SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior
  • The earnings release can be found at www.indivior.com/investors
  • The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/stcq4w5c
Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIf8e71289ddc241b399540e669d753461 

(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Logo - https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/indivior-announces-q3-2023-financial-results-301982018.html

Copyright 2023 PR Newswire

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart